--- title: 'Morning Brief — Monday, October 19, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-10-19' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-10-19' audio: 'https://media.doc.social/podcasts/morning-brief/2026-10-19.mp3' --- # Morning Brief — Monday, October 19, 2026 STERIS agrees to buy Xodus Medical, maker of Pink Pad positioning products, for $2.1 billion in cash plus up to $150 million in 2028 earnouts · Providence Medical Technology gets FDA 510(k) clearance for CORUS PCSS 3D-T, a 3D-printed porous titanium version of its posterior cervical stabilization system, debuting at NASS · JBJS RCT, 80 arthroscopic shoulder patients: surgeon-performed shoulder… ## Summary 3 stories this morning, for surgeons and the people who support them. - **STERIS agrees to buy Xodus Medical, maker of Pink Pad positioning products, for $2.1 billion in cash plus up to $150 million in 2028 earnouts** — STERIS's 8-K says it signed a purchase agreement on October 11, 2026 to acquire Xodus Medical for $2.1 billion in cash plus up to $150 million of earnout tied to 2028 targets, financed primarily with debt (a $2.0 billion JPMorgan/Goldman bridge commitment) and expected to close by December 31, 2026. MedTech Dive (https://www.medtechdive.com/news/steris-inks-21b-xodus-buyout-to-expand-consumables-portfolio/832822/) reports about $300 million of cash tax benefits, Xodus sales of about $245 million expected this year, and the Pink Pad and See Sharp product lines. [Source](https://www.sec.gov/Archives/edgar/data/1757898/000119312526420487/d165776d8k.htm) - **Providence Medical Technology gets FDA 510(k) clearance for CORUS PCSS 3D-T, a 3D-printed porous titanium version of its posterior cervical stabilization system, debuting at NASS** — Providence announced 510(k) clearance on October 13, 2026 (also reported by ORTHOWORLD, https://www.orthoworld.com/pmt-gains-510k-clearance-for-corus-pcss-3d-t/) for a porous titanium version of CORUS PCSS with the same indication and technique, claiming 1.5 times the surface area and eight times the roughness of the machined implant. The predecessor's evidence is the Providence-sponsored FUSE RCT in three-level ACDF (Spine 2025, PMID 40331720): 12-month fusion 61% with added posterior PCSS versus 17% with ACDF alone, and 24-month revision 2% versus 23%. [Source](https://www.biospace.com/press-releases/providence-medical-technology-receives-fda-510k-clearance-for-corus-pcss-3d-t-bringing-3d-printed-porous-titanium-to-its-total-segmental-fusion-platform) - **JBJS RCT, 80 arthroscopic shoulder patients: surgeon-performed shoulder field anesthesia noninferior to interscalene block on cumulative 48-hour pain, with no Horner syndrome or respiratory events** — Hasharon Hospital (Rabin Medical Center) randomized 80 arthroscopic shoulder patients to landmark-guided, phrenic-sparing shoulder field anesthesia or interscalene block. Cumulative 48-hour NRS difference was -0.82 (95% CI -1.85 to 0.21) against a 1.5-point noninferiority margin; ISB was better at 4 to 8 hours, opioid use, satisfaction and desaturation were similar, hospital stay was shorter with SFA, and ISB had two Horner syndromes and one respiratory event requiring intensive care. Published online October 16, 2026. [Source](https://pubmed.ncbi.nlm.nih.gov/42886821/) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._